Fig. 3

Dual EGFR and BRAF blockade inhibits cell proliferation and cell cycle progression in BRAF V600E thyroid carcinoma cells. a, b Cell growth (a) and cell cycle distribution (b) in BRAF V600E FRO, BCPAP and BHT101 thyroid carcinoma cell lines exposed to 1–10 μM PLX4032 or 1–10 μM gefitinib or the combination of both agents for indicated time points. Cell cycle distribution was evaluated after 24 h treatment. Statistical significance respect to vemurafenib single agent: *p < 0.05; **p < 0.005; ***p < 0.0005